PEB Investor Update – October 2021

OCTOBER 2021
REMINDER
The Retail Offer closes at 5.00pm on Wednesday 13 October 2021
If you wish to participate in the Offer, you can do so online at
https://pacificedge.capitalraise.co.nz.
To complete your acceptance online, you will need your Holder Number and the unique
Entitlement Number sent to you in the initial communications. If you require your details to be
sent to you again, please contact LINK Market Services on +64 9 375 5998.
Lux Selvanesan, New Product Development Scientist

PACIFIC EDGE INVESTOR UPDATE2
Dear Shareholder
As Australia and New Zealand tackle the recent spread of the Delta variant, we are reminded of the
challenges that have faced our US team over the past 18 months and their innovative and agile response,
that has enabled Pacific Edge to continue to grow during the resurgent pandemic. Many clinics and
hospitals have been closed and access to urologists and testing has been at best restricted, and at
times, not possible. Pacific Edge’s Patient In-Home Sampling System, virtual sales tactics and the
quick adaptation of our people to remote working have proved successful in this constantly evolving
environment. While our momentum has been hampered by the Covid environment, our team has
continued to deliver positive progress on key commercial initiatives over the FY22 year to date.
The positive momentum seen in FY21 and into the first quarter of FY22 has continued in the second
quarter with continuing growth in both test numbers and cash receipts.
Q2 HIGHLIGHTS AND EVENTS
• Pacific Edge dual listed on the Australian Securities Exchange in September 2021 and, at the same
time, we announced an equity raise to fund our growth strategy. The initial Placement was very well
subscribed by existing and targeted new Australian and international investors. Given the strong
demand, the Placement was subsequently upsized from $60m to $80m. The follow-on Retail Offer
for existing eligible shareholders is currently underway and closes on 13 October 2021. The ASX dual
listing combined with an equity raise offers a number of benefits for the Company and shareholders
including an acceleration in commercial activity and growth, access to a wider pool of healthcare and
other investors, increased liquidity and the opportunity for further analyst coverage.
• The adoption of our Cxbladder products by public healthcare providers in New Zealand has continued
to expand, with Northland and Taranaki District Health Boards now offering coverage for their
populations.
• We announced the acceptance for publication of a pivotal clinical paper outlining the significant
increase in clinical resolution that can be achieved from using multiple Cxbladder products in
the evaluation of a patient presenting to the clinic with haematuria. The paper demonstrates the
significant clinical and patient benefits from the use of a combination of Cxbladder products to
correctly identify haematuria patients, who have urothelial cancer and also, further segregate those
patients with high-impact tumours requiring priority investigation. Our long-standing strategy has
been to develop a suite of Cxbladder products that can be used alone or in combination across the
entire clinical pathway for urothelial cancer, and this is the first time that the clinical benefits of this
novel integration of Cxbladder products have been validated.
• On 30 July 2021, we held our Annual Shareholders Meeting. Fortunately this was prior to the Covid
lockdown and allowed us to meet with a number of our shareholders in person in Dunedin. All
resolutions were passed at the Meeting.
FROM THE CEO
DAVID DARLING

PACIFIC EDGE INVESTOR UPDATE3
UPDATE ON GROWTH CATALYSTS
US Sales Team
Our specialist sales people are responsible for identifying, educating and converting urologists and
healthcare institutions into commercial customers and are one of our most valuable assets. We currently
have 28 specialised account managers, up from 16 that was maintained for most of the FY21 year, and are
looking to further expand our team as we accelerate growth in the key US market. To compliment this,
we have expanded into and staffed two new sales territories and will be investing in additional marketing
activities.
Kaiser Permanente (KP)
KP started commercially using Cxbladder Monitor from December 2020, followed by Cxbladder Triage
from August 2021. Test numbers continue to grow, although momentum has been hampered by the
demands of Covid. This has impacted on patient numbers and the full electronic integration of the
Cxbladder process into Kaiser Permanente’s electronic medical records.
South East Asia
Recruitment of patients to the Singaporean study has concluded and analysis is underway. It is anticipated
that the participating urologists will draft a paper for publication in an appropriate journal over the next
few months.
CEO Recruitment
The recruitment process is well underway, with several high quality candidates now shortlisted. It is likely
the new CEO will be based in New Zealand, providing access to South East Asia and in close proximity to
Pacific Edge’s research and development team, both of which remain an important focus for the company.
While the US is currently Pacific Edge’s largest target market, a strong in-country team is already in place
with leadership from PEDUSA executive chair, David Levison and PEDUSA CEO, Jackie Walker.
Justin Harvey, Chief Technical Officer

PACIFIC EDGE INVESTOR UPDATE4
SUCCESSFUL CAPITAL RAISE TO FUND
ACCELERATED GROWTH
• Equity raising will allow Pacific Edge to capitalise on recent commercial milestones
and to accelerate the execution of its growth strategy in markets of scale
• Successful Placement upsized to $80m due to strong demand
• Placement price: $1.35 per share
• Retail Offer now underway; closing date 13 October 2021
On 23 September 2021, Pacific Edge announced it was conducting an equity raise consisting of a
placement of NZ$60 million (A$58.1 million) with a Retail Offer of up to NZ$20 million (A$19.4 million)
to eligible investors to capitalise on recent commercial milestones and to accelerate the execution of its
growth strategy in markets of scale.
The Placement was very well subscribed at the price determined in the bookbuild of NZ$1.35 (A$1.31) per
share, resulting in Pacific Edge increasing the size of the Placement from NZ$60 million (A$58.1 million) to
NZ$80 million (A$77.5 million).
We were very pleased with the demand shown for the Placement which we see as a strong endorsement
of our strategy and growth plans. We had strong support from long-term institutional investors and were
delighted to welcome several high value global growth funds to the register. The funds raised will enable
us to accelerate the growing out of our business and realising Pacific Edge’s potential.
The Retail Offer now underway will provide our existing shareholders an opportunity to further their
investment and participate in our growth. Shares will be offered at the lower of NZ$1.35, being the price
paid for shares under the Placement, and the volume weighted average price of Pacific Edge’s shares on
the NZX over the 5-day trading period up to and including the closing date of the retail offer (being
13 October 2021).
Funds raised will be used as follows:
• The majority of the funds will be used to accelerate growth in the company’s key US market;
• To further develop and grow the commercial process in Southeast Asia targeting both primary care
and secondary care physicians;
• To further leverage the company’s first mover advantage in the detection and management of
urothelial cancer;
• To potentially develop and grow new product opportunities by leveraging the company’s intellectual
property across other cancers that can be detected in urine; and
• To maintain a prudent cash buffer for balance sheet management and working capital purposes as the
company transitions to profitability.

CELEBRATIONS AS
PACIFIC EDGE JOINS THE ASX
Pacific Edge CFO Grant Gibson and CEO David Darling ringing the bell in Dunedin to celebrate the company’s dual listing on the ASX
We were delighted to join the Australian Securities Exchange (ASX) as a foreign exempt listing on
22 September 2021, with a virtual ‘ringing of the bell’ ceremony to celebrate this landmark event.
You can watch the official virtual ceremony here.
The dual listing means that our shares can now be traded on both the New Zealand stock exchange (the
NZX) and in Australia on the ASX. Shareholders need to be registered for that particular region in order to
trade shares on the relevant exchange.
The dual listing on the ASX is a logical progression for our company and a way of accessing a broader
pool of institutional and retail investors who wish to share in Pacific Edge’s success. Increasing the liquidity
of our shares and widening our investor base have been consistent strategic objectives of the Board.
Pacific Edge remains headquartered in New Zealand, with our primary listing on New Zealand Stock
Exchange.
PACIFIC EDGE INVESTOR UPDATE5

FURTHER CLINICAL VALIDATION OF
OUTPERFORMANCE OF CXBLADDER
SIGNIFICANT BENEFIT FROM COMBINED USE OF CXBLADDER TESTS
Published online in the American Urological Association’s (AUA) Journal of Urology
A pivotal, peer-reviewed paper demonstrates the significant clinical and patient benefits from the use
of a combination of Cxbladder products. The paper confirmed that the combined use of three of our
Cxbladder products for each patient, using just one urine sample, can:
- Firstly rule out those who do not have cancer;
- Then accurately identify those with cancer; and
- Finally, segregate out those with high-impact tumours for priority investigation.
This is a novel approach and integrates a number of separate molecular diagnostic analyses to yield
enhanced clinical resolution for physicians - firstly evaluating patients who have haematuria for detection
of bladder cancer and secondly, identification of patient who have High Impact Tumours (HIT) who
are then able to be prioritised. This novel approach provides significant benefit to both physicians and
patients, substantially reducing the number of patients requiring further work up while prioritising those
patients with HIT.
Of significant importance, the study concluded that the sequential use of the Cxbladder products
achieved 4.8 times greater efficiency in accurately assigning patients to the physician’s prioritisation of
investigation than the latest American Urology Association (AUA) 2020 guidelines.
Pacific Edge’s expanding portfolio
of clinical evidence drives positive
reimbursement decisions, inclusion in
clinical guidelines, wide adoption by
physicians and patient preference.
Clinical papers continue to validate
the outperformance of Cxbladder,
with a further two important
publications in a leading US urology
journal over the last three months.
Published Urologist reviewer commentary highlighted the potential for the study to “change
the diagnostic paradigm for patients presenting with hematuria, better identifying high-risk
patients and decreasing the time to tumor diagnosis.”
Read the full announcement here
PACIFIC EDGE INVESTOR UPDATE6
Rachel Hansen, Research Associate

OUTPERFORMANCE IN COVID SETTING
Published in the AUA Journal of Urology
This real world lookback in the USA, by the University of California San Francisco urologists, highlighted
the clinical utility of Cxbladder being used in the Covid setting for managing patients outside the clinic.
The lookback publication highlighted that the use of Cxbladder Monitor and Pacific Edge’s
Patient-In-Home Sampling System:
- Could be used to further stratify low risk patients for decreased surveillance during the
pandemic and beyond;
- Reduced the number of cystoscopies required; and
- Was feasible and safe for patients being monitored for urothelial cancer during the
Covid-19 pandemic.
Cairns Hospital staff specialist (urology) Dr Simon Pridgeon said it was great for the hospital to be
selected for the trial, which is being carried out at multiple locations throughout Australia.
‘This is an opportunity for us to be part of some novel research about a clinically useful tool,’ he said.
‘This tool will help us in the early detection of bladder cancer and reducing the need for unnecessary
invasive tests.
‘This means patients can be prioritised more effectively, and there are shorter waiting times for them, and
by reducing the number of patients needing invasive tests and procedures, it frees up more time for us to
assist more patients.’
Dr Pridgeon said the samples currently needed to be sent away to a laboratory for analysis, with test
results typically reported within a week.
‘We are expecting to have some results from the trial later this year, where the tests can then be used
more widely across Queensland Health,’ he said.
Read media coverage here.
PACIFIC EDGE INVESTOR UPDATE7
Cairns Hospital in Queensland,
Australia, has been selected to
participate in a trial of Cxbladder,
which is being carried out at multiple
locations across Australia.
CAIRNS HOSPITAL JOINS
AUSTRALIA-WIDE CLINICAL TRIAL

New Zealand’s public healthcare providers (District Health Boards) are leading the global adoption of
Cxbladder, and the majority have now added Cxbladder to their commercial mainstream use and their
standard of care. This provides 70% of New Zealand’s population with access to Cxbladder through
contract coverage by their public healthcare providers.
Pacific Edge’s suite of Cxbladder products are well-placed to extend their coverage under a national
clinical pathway as New Zealand’s health system consolidates towards the Māori Health Authority and
Health NZ next year.
Taranaki DHB and Northland DHB are the two latest public healthcare providers to deploy Cxbladder into
mainstream commercial use.
TARANAKI DHB is based in New Plymouth and serves a population of over 124,000, with a higher than
average number of people aged 50 years or older, a predominantly rural population and a strong Māori
presence. Under the agreement, Taranaki DHB will provide access to Cxbladder Triage, Detect, Resolve
and Monitor tests for patients throughout the region.
NORTHLAND DHB covers the northernmost part of New Zealand, serving a population of over 190,000,
of which approximately one-third are Māori and with a higher than average number of people aged 50
years or older. Under the new program, patients with blood in their urine (haematuria) will now be referred
by their primary care physician (GP) for the Cxbladder Triage test and will be able to provide a urine
specimen at their local diagnostic lab, potentially avoiding the need to travel long distances to the urology
clinic or hospital for investigation.
NEW ZEALAND LEADS THE WORLD
IN ADOPTION OF CXBLADDER
Bay of Plenty
Hauora
Tairawhiti
Northland
Hawke’s Bay
Canterbury (Includes Chatham Islands)
MidCentral
Hutt Valley
Whanganui
Taranaki
Lakes
Waitemata
Counties
Manukau
Capital & Coast
Contract Coverage of New Zealand’s
Population Using Cxbladder, August 2021
70% of New Zealand,
— over 3.5 million people —
have access to Cxbladder
Bay of Plenty
Hauora
Tairawhiti
Northland
Hawke’s Bay
Canterbury (Includes Chatham Islands)
MidCentral
Hutt Valley
Whanganui
Taranaki
Lakes
Waitemata
Counties
Manukau
Capital & Coast
Contract Coverage of New Zealand’s
Population Using Cxbladder, August 2021
70% of New Zealand,
— over 3.5 million people —
have access to Cxbladder
“The Northland DHB agreement
highlights Cxbladder’s reach in
New Zealand and draws attention
to the utility of Cxbladder for
Māori and for those in more
remote parts of New Zealand.
Instead of travelling all the way
to Whangarei to the hospital or
waiting for a regional urology
clinic to be scheduled, patients
in the Far North can get the
Cxbladder test locally under the
care of their GP thereby enabling
local physicians to make timely
referral decisions.”
Brent Pownall, VP Commercial
and Franchise, Pacific Edge.
PACIFIC EDGE INVESTOR UPDATE8

WELCOME TO
MARK GREEN, INDEPENDENT DIRECTOR
Mark Green was appointed by the Board as an Independent Director in May 2021 and elected by
shareholders at the recent Annual Meeting.
Mark is an experienced corporate finance professional, with significant capital markets and corporate
finance experience. He was an Executive Director for Investment Banking at Goldman Sachs where he
worked for nearly 20 years and has been involved in many large prominent New Zealand transactions
including the IPOs of Meridian, Mighty River Power and Vector. He has also been involved in many
domestic and international mergers, acquisitions, financings and debt issues.
Mark is a Director of a number of entities including being Chair of Astrolab VC Investment Committee and
a Director of Mariposa Holdings (a large charitable organisation supporting underprivileged women and
girls).
He is looking forward to working with the Pacific Edge team to add further value to all stakeholders
involved in the business.
PACIFIC EDGE INVESTOR UPDATE9

STAY IN TOUCH
SUBSCRIBE TO E-NEWS
Sign-up here to receive Pacific Edge
news and announcements via email
VISIT US ONLINE
www.pacificedgedx.com
www.cxbladder.com
FOLLOW US ON SOCIAL MEDIA
www.facebook.com/PacificEdgeLtd
www.facebook.com/Cxbladder
www.twitter.com/PacificEdgeLtd
www.twitter.com/Cxbladder
www.linkedin.com/company/pacific-edge-ltd
CONTACT US
87 St David Street
P O Box 56, Dunedin, New Zealand
+64 3 479 5800
investors@pacificedge.co.nz